Technical Analysis for TPTX - Turning Point Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical TPTX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | -4.03% | |
Oversold Stochastic | Weakness | -4.03% | |
Slingshot Bearish | Bearish Swing Setup | -2.33% | |
Wide Bands | Range Expansion | -2.33% | |
Oversold Stochastic | Weakness | -2.33% | |
Doji - Bullish? | Reversal | -0.91% | |
Wide Bands | Range Expansion | -0.91% | |
Down 3 Days in a Row | Weakness | -0.91% | |
Oversold Stochastic | Weakness | -0.91% | |
Wide Bands | Range Expansion | -1.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | 44 minutes ago |
Down 2 % | 44 minutes ago |
Down 1% | 44 minutes ago |
Up 1% | 44 minutes ago |
Fell Below Previous Day's Low | 44 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2021
Turning Point Therapeutics, Inc. Description
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Treatment Of Cancer Oncology Chemical Compounds Small Cell Lung Cancer Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Targeted Therapy Cancer Therapies Advanced Solid Tumors Signal Transduction Turning Protein Kinase Inhibitors Pyrrolidines Kinase
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 141.23 |
52 Week Low | 46.86 |
Average Volume | 365,482 |
200-Day Moving Average | 97.98 |
50-Day Moving Average | 107.48 |
20-Day Moving Average | 88.50 |
10-Day Moving Average | 80.75 |
Average True Range | 5.45 |
ADX | 44.83 |
+DI | 12.27 |
-DI | 30.46 |
Chandelier Exit (Long, 3 ATRs ) | 95.28 |
Chandelier Exit (Short, 3 ATRs ) | 89.38 |
Upper Bollinger Band | 107.57 |
Lower Bollinger Band | 69.44 |
Percent B (%b) | 0.2 |
BandWidth | 43.09 |
MACD Line | -9.10 |
MACD Signal Line | -8.59 |
MACD Histogram | -0.5101 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 81.63 | ||||
Resistance 3 (R3) | 81.78 | 80.47 | 80.90 | ||
Resistance 2 (R2) | 80.47 | 79.35 | 80.39 | 80.66 | |
Resistance 1 (R1) | 78.85 | 78.66 | 79.66 | 78.70 | 80.41 |
Pivot Point | 77.54 | 77.54 | 77.94 | 77.47 | 77.54 |
Support 1 (S1) | 75.93 | 76.42 | 76.73 | 75.78 | 74.07 |
Support 2 (S2) | 74.61 | 75.73 | 74.54 | 73.82 | |
Support 3 (S3) | 73.00 | 74.61 | 73.58 | ||
Support 4 (S4) | 72.85 |